Toll Free: 1-888-928-9744

Biomay AG - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Biomay AG - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Biomay AG - Product Pipeline Review - 2014', provides an overview of the Biomay AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biomay AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Biomay AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Biomay AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Biomay AG's pipeline products

Reasons to buy

- Evaluate Biomay AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Biomay AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Biomay AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Biomay AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biomay AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Biomay AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Biomay AG Snapshot 5
Biomay AG Overview 5
Key Information 5
Key Facts 5
Biomay AG - Research and Development Overview 6
Key Therapeutic Areas 6
Biomay AG - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
Biomay AG - Pipeline Products Glance 12
Biomay AG - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Biomay AG - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Biomay AG - Drug Profiles 15
BM-32 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Fish Hypoallergenic Vaccine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
BM-10 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
BM-31 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Japanese Cedar Hypoallergenic Vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Oligonucleotide for Grass Allergy 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Ragweed Hypoallergenic Vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Subunit Vaccine for Cat Allergy 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Subunit Vaccine for Mite Allergy 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Subunit Vaccine for Ragweed Allergy 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Vaccine for Grass Allergy 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Biomay AG - Pipeline Analysis 27
Biomay AG - Pipeline Products by Route of Administration 27
Biomay AG - Pipeline Products by Molecule Type 28
Biomay AG - Recent Pipeline Updates 29
Biomay AG - Dormant Projects 30
Biomay AG - Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33
List of Tables
Biomay AG, Key Information 5
Biomay AG, Key Facts 5
Biomay AG - Pipeline by Indication, 2014 7
Biomay AG - Pipeline by Stage of Development, 2014 8
Biomay AG - Monotherapy Products in Pipeline, 2014 9
Biomay AG - Out-Licensed Products in Pipeline, 2014 10
Biomay AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 11
Biomay AG - Phase II, 2014 12
Biomay AG - Phase I, 2014 13
Biomay AG - Preclinical, 2014 14
Biomay AG - Pipeline by Route of Administration, 2014 27
Biomay AG - Pipeline by Molecule Type, 2014 28
Biomay AG - Recent Pipeline Updates, 2014 29
Biomay AG - Dormant Developmental Projects,2014 30 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify